

MRI T2 lesions - Summary of new/enlarging lesion counts by visit and overall ITT population

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
New or enlarging T2 lesions at Week 156 compared to Week 108			
n	245	258	
Mean	0.2	0.0	<0.0001
SD	0.79	0.20	

(a)p-value for comparison between the active and placebo groups at Week 96 compared to baseline is based on negative binomial regression model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6) and baseline volume of T2 lesions.

natalizumab subjects had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment